CD19 CAR-T\CD22 CAR-T cell multi-target sequential therapy for relapse refractory B cell hematological malignancies - single-center, one-arm, open label study

开始日期2018-12-01

申办/合作机构

河南省人民医院

100 项与 Anti-CD20 CAR-T (Henan Provincial Peoples Hospital) 相关的临床结果

登录后查看更多信息

100 项与 Anti-CD20 CAR-T (Henan Provincial Peoples Hospital) 相关的转化医学

登录后查看更多信息

100 项与 Anti-CD20 CAR-T (Henan Provincial Peoples Hospital) 相关的专利（医药）

登录后查看更多信息

项与 Anti-CD20 CAR-T (Henan Provincial Peoples Hospital) 相关的文献（医药）

2015-04-01·Cancer immunology research1区 · 医学

Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice

1区 · 医学

Article

作者: Hochberg, Jessica ; Czuczman, Myron ; Yahr, Ashlin ; Ayello, Janet ; Cairo, Mitchell S. ; van de Ven, Carmella ; Chu, Yaya ; Barth, Matthew

Abstract:

The prognosis is very dismal for patients with relapsed CD20+ B-cell non-Hodgkin lymphoma (B-NHL). Facilitating the development of alternative novel therapeutic strategies is required to improve outcomes in patients with recurrent/refractory CD20+ B-NHL. In this study, we investigated functional activities of anti-CD20 CAR-modified, expanded peripheral blood NK cells (exPBNK) following mRNA nucleofection against CD20+ B-NHL in vitro and in vivo. CAR+ exPBNK had significantly enhanced in vitro cytotoxicity, compared with CAR− exPBNK against CD20+ Ramos (P < 0.05), Daudi, Raji, and two rituximab-resistant cell lines, Raji-2R and Raji-4RH (P < 0.001). As expected, there was no significant difference against CD20− RS4;11 and Jurkat cells. CD107a degranulation and intracellular IFNγ production were also enhanced in CAR+ exPBNK in response to CD20+ B-NHL–specific stimulation. In Raji-Luc and Raji-2R-Luc xenografted NOD/SCID/γ-chain−/− (NSG) mice, the luciferase signals measured in the CAR+ exPBNK-treated group were significantly reduced, compared with the signals measured in the untreated mice and in mice treated with the CAR− exPBNK. Furthermore, the CAR exPBNK-treated mice had significantly extended survival time (P < 0.001) and reduced tumor size, compared with those of the untreated and the CAR− exPBNK-treated mice (P < 0.05). These preclinical data suggest that ex vivo–exPBNK modified with anti-CD20 CAR may have therapeutic potential for treating patients with poor-risk CD20+ hematologic malignancies. Cancer Immunol Res; 3(4); 333–44. ©2014 AACR.

项与 Anti-CD20 CAR-T (Henan Provincial Peoples Hospital) 相关的新闻（医药）

2024-12-08

·ornatx.com

In Vivo panCAR-Mediated Depletion of B cells in Non-Human Primates Using a Circular (oRNA®) Anti-CD20 CAR

WATERTOWN, Mass., November 5, 2024 – Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines and unprecedented lipid nanoparticle (LNP) delivery solutions for oncology and autoimmune diseases, today announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego from December 7-10, 2024. The presentation will outline data supporting the exploration of its in vivo CAR therapy approach in oncology and autoimmune diseases. Presentation details are as follows: Title: In Vivo panCAR-Mediated Depletion of B cells in Non-Human Primates Using a Circular (oRNA®) Anti-CD20 CAR Speaker: Dr. Akinola Emmanuel, Principal Scientist, Drug Discovery, Orna Therapeutics Date/Time: Sunday, December 8, 20246:00 PM – 8:00 PMPT Publication Number: 3427 Session Name: 702. CAR-T Cell Therapies: Basic and Translational: Poster II About Orna Therapeutics Orna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA®) therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Orna’s circular RNA transcripts have advantages over traditional mRNA approaches, including simplified production, improved formulation into lipid nanoparticles, and superior protein expression. Its industry-leading LNP-based delivery systems and comprehensive editing programs position Orna to advance novel RNA medicines with vast potential to transform patient care. To learn more, visit: www.ornatx.com and follow Orna Therapeutics on Twitter and LinkedIn. Investor Contact: Investor-relations@ornatx.com Media Contact: Peg Rusconi Deerfield Group Peg.rusconi@deerfieldgroup.com

ASH会议细胞疗法

100 项与 Anti-CD20 CAR-T (Henan Provincial Peoples Hospital) 相关的药物交易

登录后查看更多信息